USANA Health Sciences (NYSE:USNA) Stock Rating Lowered by Zacks Research

Key Points

• USANA Health Sciences has been downgraded from a "hold" rating to a "strong sell" rating by Zacks Research, reflecting a trend of negative sentiment from various analysts.
• The company's stock opened at $20.82 and has a consensus price target of $36.00, indicating potential for recovery despite recent downgrades.
• Insider trading activity shows a significant decrease in ownership, with key insiders selling portions of their stock, raising concerns about investor confidence.

USANA Health Sciences (NYSE:USNA - Get Free Report) was downgraded by investment analysts at Zacks Research from a "hold" rating to a "strong sell" rating in a research note issued on Tuesday,Zacks.com reports.

Several other equities research analysts also recently weighed in on USNA. Weiss Ratings reissued a "sell (d+)" rating on shares of USANA Health Sciences in a research report on Wednesday, October 8th. Wall Street Zen downgraded shares of USANA Health Sciences from a "buy" rating to a "hold" rating in a research report on Saturday, October 11th. Two analysts have rated the stock with a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Reduce" and a consensus price target of $36.00.

USANA Health Sciences Stock Performance

USNA stock opened at $20.82 on Tuesday. The firm has a market capitalization of $380.29 million, a price-to-earnings ratio of 11.56, a PEG ratio of 1.03 and a beta of 0.61. The firm has a 50 day moving average price of $28.25 and a 200-day moving average price of $28.95. USANA Health Sciences has a 52-week low of $19.88 and a 52-week high of $41.83.

USANA Health Sciences (NYSE:USNA - Get Free Report) last announced its quarterly earnings results on Thursday, October 9th. The company reported $0.56 earnings per share for the quarter. The company had revenue of $200.22 million during the quarter. USANA Health Sciences had a net margin of 3.79% and a return on equity of 9.48%. USANA Health Sciences has set its Q3 2025 guidance at -0.150--0.150 EPS. As a group, sell-side analysts forecast that USANA Health Sciences will post 2.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider David Mulham Mulham sold 3,515 shares of the business's stock in a transaction on Wednesday, July 30th. The shares were sold at an average price of $30.26, for a total transaction of $106,363.90. Following the completion of the sale, the insider owned 9,260 shares of the company's stock, valued at $280,207.60. The trade was a 27.51% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Gilbert A. Fuller sold 1,058 shares of the business's stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $29.10, for a total transaction of $30,787.80. The disclosure for this sale can be found here. Insiders own 0.63% of the company's stock.

Institutional Investors Weigh In On USANA Health Sciences

A number of hedge funds have recently modified their holdings of the business. Teacher Retirement System of Texas bought a new position in USANA Health Sciences in the 1st quarter worth $888,000. US Bancorp DE boosted its holdings in USANA Health Sciences by 13.1% in the 1st quarter. US Bancorp DE now owns 4,611 shares of the company's stock worth $124,000 after buying an additional 535 shares during the period. Pzena Investment Management LLC boosted its holdings in USANA Health Sciences by 9.4% in the 2nd quarter. Pzena Investment Management LLC now owns 1,198,260 shares of the company's stock worth $36,583,000 after buying an additional 103,074 shares during the period. Hsbc Holdings PLC boosted its holdings in USANA Health Sciences by 87.9% in the 1st quarter. Hsbc Holdings PLC now owns 14,750 shares of the company's stock worth $403,000 after buying an additional 6,902 shares during the period. Finally, Petrus Trust Company LTA bought a new position in USANA Health Sciences in the 1st quarter worth $362,000. Institutional investors own 54.25% of the company's stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.